Not to be given to patients w/ severe hepatic impairment or significant liver disease, gallstones or gallbladder disorders, or hypoalbuminaemic states eg, nephrotic syndrome. Secondary causes of hyperlipidemia eg, uncontrolled type 2 DM, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, alcoholism, pharmacological treatment w/ diuretics, β-blocking agents, estrogens, progestogens, combined OCs, immunosuppressive agents & PIs. Adjust dose in patients whose estimated GFR is 30-59 mL/min/1.73 m
2. Measure creatinine during the 1st 3 mth after initiation of treatment & periodically thereafter. Monitor transaminase levels every 3 mth during the 1st 12 mth of treatment & periodically thereafter. Discontinue therapy when symptoms indicative of hepatitis occurs (eg, jaundice, pruritus), & diagnosis is confirmed by lab testing. Pancreatitis. Muscle toxicity; patients w/ pre-disposing factors for myopathy &/or rhabdomyolysis, including >70 yr, personal or familial history of hereditary muscular disorders, renal impairment, hypothyroidism & high alcohol intake. Co-prescription w/ an HMG-CoA reductase inhibitor or another fibrate. Contains lactose; rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Mild to moderate renal insufficiency. Pregnancy & lactation.
Sign Out
